SK bioscience, a vaccine and biotech company, has made an equity investment in Novavax, a global company developing protein-based vaccines with its Matrix-M adjuvant, securing 6.5 million shares of common stock through a private placement. SK bioscience’s strategic equity investment comes at a time when the two companies aim to transition from a CMO/CDMO partnership formed during the pandemic to a long-term synergistic relationship. Along with the equity investment, SK bioscience and...